Brokerages Set Edwards Lifesciences Co. (NYSE:EW) PT at $79.40

Shares of Edwards Lifesciences Co. (NYSE:EW) have received an average rating of “Hold” from the twenty-six analysts that are presently covering the company, MarketBeat reports. Fifteen research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $79.40.

A number of research analysts have weighed in on the company. Barclays increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. Evercore ISI decreased their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Finally, Robert W. Baird lowered their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,500 shares of company stock valued at $2,160,800 in the last quarter. Company insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the stock. Purus Wealth Management LLC raised its stake in Edwards Lifesciences by 5.2% during the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock valued at $297,000 after buying an additional 160 shares in the last quarter. JFS Wealth Advisors LLC increased its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 166 shares during the last quarter. Seascape Capital Management raised its position in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock valued at $2,177,000 after acquiring an additional 174 shares in the last quarter. Cooper Financial Group lifted its stake in Edwards Lifesciences by 2.8% during the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock worth $479,000 after purchasing an additional 175 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. boosted its holdings in Edwards Lifesciences by 1.2% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock worth $1,417,000 after purchasing an additional 184 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 3.0 %

Edwards Lifesciences stock opened at $71.20 on Thursday. The stock has a 50-day moving average price of $71.73 and a 200 day moving average price of $71.77. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a market cap of $41.99 billion, a PE ratio of 10.27, a P/E/G ratio of 3.61 and a beta of 1.11. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.59 earnings per share. Equities research analysts predict that Edwards Lifesciences will post 2.56 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.